Log in
LON:AZN

AstraZeneca PLC (AZN.L) Competitors

GBX 8,123
+180.00 (+2.27 %)
(As of 10/27/2020 09:39 AM ET)
Add
Compare
Today's Range
8,077
Now: GBX 8,123
8,146
50-Day Range
7,920
MA: GBX 8,385.26
8,812
52-Week Range
5,871
Now: GBX 8,123
£101.20
Volume163,616 shs
Average Volume1.99 million shs
Market Capitalization£106.60 billion
P/E Ratio49.62
Dividend Yield2.73%
BetaN/A

Competitors

AstraZeneca PLC (AZN.L) (LON:AZN) Vs. GSK, DPH, HCM, VEC, BXP, and EAH

Should you be buying AZN stock or one of its competitors? Companies in the industry of "drug manufacturers - major" are considered alternatives and competitors to AstraZeneca PLC (AZN.L), including GlaxoSmithKline plc (GSK.L) (GSK), Dechra Pharmaceuticals (DPH), Hutchison China MediTech (HCM), Vectura Group (VEC), Beximco Pharmaceuticals Limited (BXP.L) (BXP), and ECO Animal Health Group plc (EAH.L) (EAH).

AstraZeneca PLC (AZN.L) (LON:AZN) and GlaxoSmithKline plc (GSK.L) (LON:GSK) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, earnings and profitability.

Valuation and Earnings

This table compares AstraZeneca PLC (AZN.L) and GlaxoSmithKline plc (GSK.L)'s gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AstraZeneca PLC (AZN.L)£25.70 billion4.15N/AGBX 163.7049.62
GlaxoSmithKline plc (GSK.L)£35.00 billion1.93N/AGBX 132.7010.13

GlaxoSmithKline plc (GSK.L) is trading at a lower price-to-earnings ratio than AstraZeneca PLC (AZN.L), indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares AstraZeneca PLC (AZN.L) and GlaxoSmithKline plc (GSK.L)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AstraZeneca PLC (AZN.L)N/AN/AN/A
GlaxoSmithKline plc (GSK.L)N/AN/AN/A

Dividends

AstraZeneca PLC (AZN.L) pays an annual dividend of GBX 216 per share and has a dividend yield of 2.7%. GlaxoSmithKline plc (GSK.L) pays an annual dividend of GBX 76 per share and has a dividend yield of 5.7%. AstraZeneca PLC (AZN.L) pays out 131.9% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. GlaxoSmithKline plc (GSK.L) pays out 57.3% of its earnings in the form of a dividend. GlaxoSmithKline plc (GSK.L) is clearly the better dividend stock, given its higher yield and lower payout ratio.

Analyst Recommendations

This is a summary of recent ratings and target prices for AstraZeneca PLC (AZN.L) and GlaxoSmithKline plc (GSK.L), as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AstraZeneca PLC (AZN.L)621202.30
GlaxoSmithKline plc (GSK.L)39702.21

AstraZeneca PLC (AZN.L) presently has a consensus target price of GBX 8,421.18, suggesting a potential upside of 4.26%. GlaxoSmithKline plc (GSK.L) has a consensus target price of GBX 1,815.19, suggesting a potential upside of 34.98%. Given GlaxoSmithKline plc (GSK.L)'s higher possible upside, analysts clearly believe GlaxoSmithKline plc (GSK.L) is more favorable than AstraZeneca PLC (AZN.L).

Summary

AstraZeneca PLC (AZN.L) beats GlaxoSmithKline plc (GSK.L) on 5 of the 9 factors compared between the two stocks.

Dechra Pharmaceuticals (LON:DPH) and AstraZeneca PLC (AZN.L) (LON:AZN) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, dividends, analyst recommendations, earnings and profitability.

Earnings & Valuation

This table compares Dechra Pharmaceuticals and AstraZeneca PLC (AZN.L)'s revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dechra Pharmaceuticals£515.10 million7.44N/AGBX 32.80108.11
AstraZeneca PLC (AZN.L)£25.70 billion4.15N/AGBX 163.7049.62

AstraZeneca PLC (AZN.L) is trading at a lower price-to-earnings ratio than Dechra Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Dechra Pharmaceuticals and AstraZeneca PLC (AZN.L)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Dechra PharmaceuticalsN/AN/AN/A
AstraZeneca PLC (AZN.L)N/AN/AN/A

Dividends

Dechra Pharmaceuticals pays an annual dividend of GBX 34 per share and has a dividend yield of 1.0%. AstraZeneca PLC (AZN.L) pays an annual dividend of GBX 216 per share and has a dividend yield of 2.7%. Dechra Pharmaceuticals pays out 103.7% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. AstraZeneca PLC (AZN.L) pays out 131.9% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Dechra Pharmaceuticals and AstraZeneca PLC (AZN.L), as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Dechra Pharmaceuticals02202.50
AstraZeneca PLC (AZN.L)621202.30

Dechra Pharmaceuticals currently has a consensus price target of GBX 3,077.50, suggesting a potential downside of 13.60%. AstraZeneca PLC (AZN.L) has a consensus price target of GBX 8,421.18, suggesting a potential upside of 4.26%. Given AstraZeneca PLC (AZN.L)'s higher possible upside, analysts plainly believe AstraZeneca PLC (AZN.L) is more favorable than Dechra Pharmaceuticals.

Summary

AstraZeneca PLC (AZN.L) beats Dechra Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

Hutchison China MediTech (LON:HCM) and AstraZeneca PLC (AZN.L) (LON:AZN) are both companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, dividends, analyst recommendations, earnings and profitability.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Hutchison China MediTech and AstraZeneca PLC (AZN.L), as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Hutchison China MediTech02002.00
AstraZeneca PLC (AZN.L)621202.30

Hutchison China MediTech currently has a consensus price target of GBX 360, suggesting a potential downside of 20.53%. AstraZeneca PLC (AZN.L) has a consensus price target of GBX 8,421.18, suggesting a potential upside of 4.26%. Given AstraZeneca PLC (AZN.L)'s stronger consensus rating and higher possible upside, analysts plainly believe AstraZeneca PLC (AZN.L) is more favorable than Hutchison China MediTech.

Valuation & Earnings

This table compares Hutchison China MediTech and AstraZeneca PLC (AZN.L)'s gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hutchison China MediTech£209.46 million15.09N/AGBX (16.40)-27.12
AstraZeneca PLC (AZN.L)£25.70 billion4.15N/AGBX 163.7049.62

Hutchison China MediTech is trading at a lower price-to-earnings ratio than AstraZeneca PLC (AZN.L), indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Hutchison China MediTech and AstraZeneca PLC (AZN.L)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Hutchison China MediTechN/AN/AN/A
AstraZeneca PLC (AZN.L)N/AN/AN/A

Summary

AstraZeneca PLC (AZN.L) beats Hutchison China MediTech on 6 of the 7 factors compared between the two stocks.

AstraZeneca PLC (AZN.L) (LON:AZN) and Vectura Group (LON:VEC) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, earnings, profitability, dividends and valuation.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for AstraZeneca PLC (AZN.L) and Vectura Group, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AstraZeneca PLC (AZN.L)621202.30
Vectura Group01302.75

AstraZeneca PLC (AZN.L) currently has a consensus price target of GBX 8,421.18, suggesting a potential upside of 4.26%. Vectura Group has a consensus price target of GBX 124.50, suggesting a potential upside of 18.35%. Given Vectura Group's stronger consensus rating and higher probable upside, analysts clearly believe Vectura Group is more favorable than AstraZeneca PLC (AZN.L).

Earnings and Valuation

This table compares AstraZeneca PLC (AZN.L) and Vectura Group's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AstraZeneca PLC (AZN.L)£25.70 billion4.15N/AGBX 163.7049.62
Vectura Group£176.30 million3.56N/AGBX (1.20)-87.67

Vectura Group is trading at a lower price-to-earnings ratio than AstraZeneca PLC (AZN.L), indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares AstraZeneca PLC (AZN.L) and Vectura Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AstraZeneca PLC (AZN.L)N/AN/AN/A
Vectura GroupN/AN/AN/A

Summary

AstraZeneca PLC (AZN.L) beats Vectura Group on 5 of the 7 factors compared between the two stocks.

AstraZeneca PLC (AZN.L) (LON:AZN) and Beximco Pharmaceuticals Limited (BXP.L) (LON:BXP) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, earnings, profitability, dividends and valuation.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for AstraZeneca PLC (AZN.L) and Beximco Pharmaceuticals Limited (BXP.L), as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AstraZeneca PLC (AZN.L)621202.30
Beximco Pharmaceuticals Limited (BXP.L)0000N/A

AstraZeneca PLC (AZN.L) currently has a consensus price target of GBX 8,421.18, suggesting a potential upside of 4.26%. Given AstraZeneca PLC (AZN.L)'s higher probable upside, equities analysts clearly believe AstraZeneca PLC (AZN.L) is more favorable than Beximco Pharmaceuticals Limited (BXP.L).

Earnings and Valuation

This table compares AstraZeneca PLC (AZN.L) and Beximco Pharmaceuticals Limited (BXP.L)'s top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AstraZeneca PLC (AZN.L)£25.70 billion4.15N/AGBX 163.7049.62
Beximco Pharmaceuticals Limited (BXP.L)N/AN/AN/AN/AN/A

Dividends

AstraZeneca PLC (AZN.L) pays an annual dividend of GBX 216 per share and has a dividend yield of 2.7%. Beximco Pharmaceuticals Limited (BXP.L) pays an annual dividend of GBX 1 per share and has a dividend yield of 1.7%. AstraZeneca PLC (AZN.L) pays out 131.9% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.

Profitability

This table compares AstraZeneca PLC (AZN.L) and Beximco Pharmaceuticals Limited (BXP.L)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AstraZeneca PLC (AZN.L)N/AN/AN/A
Beximco Pharmaceuticals Limited (BXP.L)N/AN/AN/A

Summary

AstraZeneca PLC (AZN.L) beats Beximco Pharmaceuticals Limited (BXP.L) on 4 of the 5 factors compared between the two stocks.

AstraZeneca PLC (AZN.L) (LON:AZN) and ECO Animal Health Group plc (EAH.L) (LON:EAH) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, earnings, profitability, dividends and valuation.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for AstraZeneca PLC (AZN.L) and ECO Animal Health Group plc (EAH.L), as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AstraZeneca PLC (AZN.L)621202.30
ECO Animal Health Group plc (EAH.L)00103.00

AstraZeneca PLC (AZN.L) currently has a consensus price target of GBX 8,421.18, suggesting a potential upside of 4.26%. ECO Animal Health Group plc (EAH.L) has a consensus price target of GBX 430, suggesting a potential upside of 77.32%. Given ECO Animal Health Group plc (EAH.L)'s stronger consensus rating and higher probable upside, analysts clearly believe ECO Animal Health Group plc (EAH.L) is more favorable than AstraZeneca PLC (AZN.L).

Earnings and Valuation

This table compares AstraZeneca PLC (AZN.L) and ECO Animal Health Group plc (EAH.L)'s top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AstraZeneca PLC (AZN.L)£25.70 billion4.15N/AGBX 163.7049.62
ECO Animal Health Group plc (EAH.L)£73.37 million2.23N/AGBX 13.3018.23

ECO Animal Health Group plc (EAH.L) is trading at a lower price-to-earnings ratio than AstraZeneca PLC (AZN.L), indicating that it is currently the more affordable of the two stocks.

Dividends

AstraZeneca PLC (AZN.L) pays an annual dividend of GBX 216 per share and has a dividend yield of 2.7%. ECO Animal Health Group plc (EAH.L) pays an annual dividend of GBX 15 per share and has a dividend yield of 6.2%. AstraZeneca PLC (AZN.L) pays out 131.9% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. ECO Animal Health Group plc (EAH.L) pays out 112.8% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. ECO Animal Health Group plc (EAH.L) is clearly the better dividend stock, given its higher yield and lower payout ratio.

Profitability

This table compares AstraZeneca PLC (AZN.L) and ECO Animal Health Group plc (EAH.L)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AstraZeneca PLC (AZN.L)N/AN/AN/A
ECO Animal Health Group plc (EAH.L)N/AN/AN/A

Summary

AstraZeneca PLC (AZN.L) beats ECO Animal Health Group plc (EAH.L) on 5 of the 9 factors compared between the two stocks.


AstraZeneca PLC (AZN.L) Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
GlaxoSmithKline plc (GSK.L) logo
GSK
GlaxoSmithKline plc (GSK.L)
2.6$1,344.80+0.1%£72.48 billion£35.00 billion10.13Upcoming Earnings
Dechra Pharmaceuticals logo
DPH
Dechra Pharmaceuticals
0.7$3,546.00+0.6%£3.47 billion£515.10 million108.11
Hutchison China MediTech logo
HCM
Hutchison China MediTech
0.8$444.84+3.2%£3.38 billion£209.46 million-27.12
Vectura Group logo
VEC
Vectura Group
1.2$105.20+0.6%£600.65 million£176.30 million-87.67
Beximco Pharmaceuticals Limited (BXP.L) logo
BXP
Beximco Pharmaceuticals Limited (BXP.L)
0.6$60.00+2.5%£233.20 millionN/A0.00
ECO Animal Health Group plc (EAH.L) logo
EAH
ECO Animal Health Group plc (EAH.L)
1.9$242.50+0.0%£140.16 million£73.37 million18.23
Allergy Therapeutics logo
AGY
Allergy Therapeutics
0.9$13.28+0.8%£97.19 million£78.20 million12.07
Futura Medical plc (FUM.L) logo
FUM
Futura Medical plc (FUM.L)
1.2$14.63+2.6%£32.91 million£31,778.00-5.85
SAR
Sareum Holdings plc (SAR.L)
0.5$2.83+37.6%£26.21 million£47,204.00-7.15High Trading Volume
CTI
Cathay International
0.8$1.15+10.9%£24.40 million£76.68 million5.75
N4 Pharma Plc (N4P.L) logo
N4P
N4 Pharma Plc (N4P.L)
0.5$7.08+5.9%£8.90 million£23,524.00-8.85
Sinclair Pharma plc (SPH.L) logo
SPH
Sinclair Pharma plc (SPH.L)
0.6$31.80+0.0%£0.00N/A0.00
This page was last updated on 10/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.